--- title: "Pre-market hot trades in US stocks: Guidewire Software pre-market down 10.91%; HCA Healthcare pre-market down 7.87%" type: "News" locale: "en" url: "https://longbridge.com/en/news/292617871.md" description: "Guidewire Software pre-market down 10.91%; HCA Healthcare pre-market down 7.87%; NextCure pre-market up 316.51%; Shuttle Pharmaceuticals pre-market up 45.17%; Vision Marine Tech pre-market up 31.91%" datetime: "2026-07-14T11:37:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292617871.md) - [en](https://longbridge.com/en/news/292617871.md) - [zh-HK](https://longbridge.com/zh-HK/news/292617871.md) generator: "portal-rs" --- # Pre-market hot trades in US stocks: Guidewire Software pre-market down 10.91%; HCA Healthcare pre-market down 7.87% **Popular Pre-Market Trades in US Stocks** Guidewire is down 10.91% in pre-market. Based on recent key news: 1. On July 13, Michael George Rosenbaum, CEO of Guidewire Software, sold 1,200 shares of common stock at a price of $138.47 per share. This sale may raise concerns about insider confidence in the company, leading to a decline in stock price. Source: EDGAR system disclosure. 2. On July 14, MarketBeat reported that despite Guidewire Software receiving a moderate buy rating from analysts, top analysts believe there are five other stocks that are more worthy of purchase. This may weaken investor confidence in Guidewire, further impacting the stock price. Source: MarketBeat. 3. No other significant news recently. The technology sector has seen increased volatility recently, which needs attention. HCA Healthcare is down 7.87% in pre-market. Based on recent key news: 1. On July 14, HCA Healthcare reported a net income of $1.699 billion for the second quarter, with earnings per share of $7.62. Although the financial report shows strong profitability, the full-year revenue expectation is between $77 billion and $79.5 billion, slightly below the market expectation of $78.712 billion, leading to a decline in stock price. 2. On July 14, MarketBeat's analysis showed that although HCA Healthcare was rated as "moderate buy," top analysts are more optimistic about five other stocks. This relatively unfavorable analyst rating has affected investor confidence, further exacerbating the decline in stock price. The healthcare industry faces policy uncertainties, with significant capital outflows. **Top Gainers in Pre-Market US Stocks** NextCure is up 316.51% in pre-market. Based on recent key news: 1. On July 14, NextCure announced a merger with Avere Therapeutics, and the merged entity will operate under the name Avere Therapeutics. This news has driven NextCure's stock price significantly higher, with a pre-market increase of 316.51%. 2. On July 14, NextCure also announced that it has secured $320 million in private financing to develop AVR-001, an experimental drug for inflammatory diseases. This financing plan has enhanced market confidence in the company's future development, further driving up the stock price. 3. On July 14, the merger agreement stipulates that Avere's shareholders will hold approximately 98.8% of the merged company's shares, while NextCure shareholders will hold only about 1.2%. This adjustment in equity structure has attracted market attention, leading to stock price fluctuations. The biotechnology industry has seen frequent merger activities recently, garnering high market interest Shuttle Pharmaceuticals pre-market rose 45.17%. Based on recent news, 4. On July 13, HRT Financial LP increased its direct holdings in Shuttle Pharmaceuticals to 61,271 shares. HRT Financial purchased 8,997 shares on the open market at prices ranging from $3.11 to $3.38 per share. Following this news, demand for the stock significantly increased, driving the stock price up sharply. 5. On July 13, HRT Financial reported in Form 3 that its stake in Shuttle Pharmaceuticals reached 10%. As of July 9, HRT Financial directly held 60,540 shares of common stock. The news of this increase in holdings further boosted market confidence, leading to a rise in the stock price. Demand for the stock significantly increased, driving the stock price up sharply. Vision Marine Tech pre-market rose 31.91%. Based on recent news, 1. On July 13, Vision Marine Technologies announced the latest financial and operational information. The announcement was released through the EDGAR system of the U.S. Securities and Exchange Commission, showing that the company has made significant progress in technology development and commercialization, boosting market confidence and driving the stock price up. 2. On July 9, HRT Financial sold its 34,746 shares of Vision Marine Technologies common stock at a price of $1.25 per share. Although HRT Financial liquidated its holdings, the market's optimistic expectations for the company's future development still drove the stock price up. 3. Recently, Vision Marine Technologies' stock price approached a 52-week low of $1.00, attracting some investors to buy the dip, further driving the stock price rebound. Supply chain disruptions and competitive pressures remain major risks ### Related Stocks - [GWRE.US](https://longbridge.com/en/quote/GWRE.US.md) - [HCA.US](https://longbridge.com/en/quote/HCA.US.md) - [NXTC.US](https://longbridge.com/en/quote/NXTC.US.md) - [SHPH.US](https://longbridge.com/en/quote/SHPH.US.md) - [VMAR.US](https://longbridge.com/en/quote/VMAR.US.md) ## Related News & Research - [Guidewire Software (GWRE) Following Qusar AI Launch Has Fair Value Back In Focus](https://longbridge.com/en/news/296098862.md) - [GUIDEWIRE TO ANNOUNCE FOURTH QUARTER & FISCAL YEAR 2026 FINANCIAL RESULTS ON SEPTEMBER 3, 2026 | GWRE Stock News](https://longbridge.com/en/news/296532442.md) - [1ST Source Bank Invests $3.38 Million in HCA Healthcare, Inc. $HCA](https://longbridge.com/en/news/296066817.md) - [HCA Healthcare, Inc. to Present at September Conferences | HCA Stock News](https://longbridge.com/en/news/296536002.md) - [Guidewire President John P. Mullen disposes of 14,400 shares worth $2.66 million](https://longbridge.com/en/news/296532011.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**